Cardiovascular comorbidities in psoriasis (Review)

Brănişteanu, D; Nicolescu, Alin; Brănișteanu, Dumitru; Branisteanu, Catalina Ioana; Drăgoi, Andreea; Bogdănici, Camelia Margareta; Toader, Mihaela Paula; Tucaliuc, Andreea; Dimitriu, Andreea; Daogaru, Doru; Pîrvulescu, Ruxandra; Porumb-Andrese, Elena

doi:10.3892/etm.2021.11075

Cited by 18 publications

(19 citation statements)

References 35 publications

(49 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Compared to healthy individuals, psoriasis patients have an increased risk of developing comorbidities, including cardiovascular disease, hypertension, obesity, and diabetes mellitus (rev. in [ 2 , 3 ]). A higher risk of cardiovascular, metabolic, and other disorders suggest that psoriasis is systemic, and in addition to the skin, it also damages other tissues and organs.…”

Section: Introductionmentioning

confidence: 99%

The Role of Transcription Factor PPAR-γ in the Pathogenesis of Psoriasis, Skin Cells, and Immune Cells

Соболев

Tchepourina

Korsunskaya

et al. 2022

IJMS

View full text Add to dashboard Cite

The peroxisome proliferator-activated receptor PPAR-γ is one of three PPAR nuclear receptors that act as ligand-activated transcription factors. In immune cells, the skin, and other organs, PPAR-γ regulates lipid, glucose, and amino acid metabolism. The receptor translates nutritional, pharmacological, and metabolic stimuli into the changes in gene expression. The activation of PPAR-γ promotes cell differentiation, reduces the proliferation rate, and modulates the immune response. In the skin, PPARs also contribute to the functioning of the skin barrier. Since we know that the route from identification to the registration of drugs is long and expensive, PPAR-γ agonists already approved for other diseases may also represent a high interest for psoriasis. In this review, we discuss the role of PPAR-γ in the activation, differentiation, and proliferation of skin and immune cells affected by psoriasis and in contributing to the pathogenesis of the disease. We also evaluate whether the agonists of PPAR-γ may become one of the therapeutic options to suppress the inflammatory response in lesional psoriatic skin and decrease the influence of comorbidities associated with psoriasis.

show abstract

Section: Introductionmentioning

confidence: 99%

The Role of Transcription Factor PPAR-γ in the Pathogenesis of Psoriasis, Skin Cells, and Immune Cells

Соболев

Tchepourina

Korsunskaya

et al. 2022

IJMS

View full text Add to dashboard Cite

show abstract

“…Interleukin-12 enhances the activation of T-helper-1, seen in the case of psoriasis and atherosclerosis, both. Hence this shows the relationship between the pathophysiology of psoriasis and atherosclerosis [4,5].…”

Section: Introductionmentioning

confidence: 75%

“…Therapy by statin has proved to reduce the cases of myocardial infarction. Compared to patients with CVD (not secondary to psoriasis), psoriasis patients using high-intensity statins showed a comparable decrease in lipids and cardiovascular events, demonstrating the effectiveness of statins in this high-risk population [5].…”

Section: Clinical Management For Cardiovascular Diseases In Cases Of ...mentioning

confidence: 83%

Psoriasis a Cause of Cardiovascular Diseases: A Review Article

Gupta¹,

Madke²

2022

Cureus

View full text Add to dashboard Cite

Psoriasis is a severe, chronic inflammatory disease characterized by erythematous plaques across the extensor surfaces of the skin. Psoriasis has been linked to a higher threat of vascular events like myocardial infarction and stroke. Other associated cardiovascular disorders in the case of psoriasis include building up atherosclerosis, non-ischemic dilated cardiomyopathy, and psoriatic arthritis. Individuals can use International Classification of Diseases (ICD-9) codes to identify cardiovascular disease/comorbidities and related risk factors. The relation between pathophysiology and mechanism of psoriasis and the building up of fat and cholesterol in or on the arterial walls makes the association between psoriasis and cardiovascular diseases more obvious. There is very little research on the adverse effect of systemic treatment of psoriasis on cardiovascular events. Treatment of psoriasis includes mainly biologics and systemic therapy, including methotrexate as a first-line drug. An indirect relation between psoriasis-arthritis and cardiovascular diseases is being noted. Various risk factors contribute to psoriasis and are associated with cardiovascular disease, including smoking, hypertension, and obesity. Personal management to decrease the threat to the cardiovascular system in case of psoriasis can be achieved by changing lifestyle, which includes exercising and avoiding smoking. The criteria for identifying metabolic syndrome are discussed in this review article. Figure Rating Scales (FRS) were used for studying the risk prediction of various cardiovascular diseases. Individuals with atherosclerosis, hypertension and diabetes mellitus type-2 are at a higher risk of developing cardiovascular events and multiple chronic conditions in the case of psoriasis; hence they are part of the population at risk.

show abstract

“…Psoriasis promotes insulin resistance [23] which increases the demand for insulin secretion from pancreatic β-cells to maintain the glucose homeostasis and even in normoglycemic patients can lead to atherosclerosis, myocardial dysfunction and major cardiovascular events [24].…”

Section: Discussionmentioning

confidence: 99%

Psoriatic arthritis and psoriasis severity as metabolic syndrome and insulin resistance predictors

et al. 2022

View full text Add to dashboard Cite

Introduction/Objective. The aim of this study was to evaluate psoriasis severity and psoriatic arthritis (PsA) as metabolic syndrome (MetS) and insulin resistance (IR) predictors in patients with chronic plaque psoriasis as well as to evaluate if psoriasis severity and PsA are independent predictors for IR regardless of the MetS presence. Methods. This prospective, observational descriptive cross-sectional study was conducted at Dermatovenereological Clinic of the University Clinical Centre of Vojvodina, and included a total of 105 psoriasis patients divided into three groups: group with mild psoriasis (Psoriasis Area Severity Index ? PASI score < 10), group with moderate to severe psoriasis (PASI ?10), and group with PsA diagnosed on the basis of the CASPAR criteria. Results. Percentage of patients who had MetS was higher in the group with the severe form of psoriasis (p < 0.05) as well as IR (p = 0.05). PsA was also more frequently associated with MetS (p = 0.05) and IR (p < 0.01). In patients without MetS, no association between psoriasis severity and IR was found (p = 1.0), although there was a positive correlation between PASI and index of ?-cells secretory capacity % (HOMA B), which shows tendency for IR development. The association between PsA and presence of IR in patients without MetS was statistically significant (p < 0.05). Conclusion. MetS and IR prevalence increases in patients with PsA and in patients with the moderate and severe form of chronic plaque psoriasis. Both psoriasis severity and PsA are independent predictors for IR regardless of the MetS presence.

show abstract

Cardiovascular comorbidities in psoriasis (Review)

Cited by 18 publications

References 35 publications

The Role of Transcription Factor PPAR-γ in the Pathogenesis of Psoriasis, Skin Cells, and Immune Cells

The Role of Transcription Factor PPAR-γ in the Pathogenesis of Psoriasis, Skin Cells, and Immune Cells

Psoriasis a Cause of Cardiovascular Diseases: A Review Article

Psoriatic arthritis and psoriasis severity as metabolic syndrome and insulin resistance predictors

Contact Info

Product

Resources

About